Get access

Small platelet microparticle levels are increased in pulmonary arterial hypertension

Authors

  • Sophie Nadaud,

    1. INSERM UMR_S 956, Paris, France
    2. UPMC Univ Paris 06, Paris, France
    3. ICAN Institute for Cardiometabolism and Nutrition, Paris, France
    Search for more papers by this author
    • These authors equally contributed to the work.

  • Odette Poirier,

    1. INSERM UMR_S 956, Paris, France
    2. UPMC Univ Paris 06, Paris, France
    3. ICAN Institute for Cardiometabolism and Nutrition, Paris, France
    Search for more papers by this author
    • These authors equally contributed to the work.

  • Barbara Girerd,

    1. Université Paris-Sud, Faculté de Médecine, Kremlin-Bicêtre, Paris, France
    2. AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, DHU TORINO «Thorax Innovation», Hôpital de Bicêtre, Le Kremlin-Bicêtre, Paris, France
    3. INSERM UMR_S 999, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, LabEx LERMIT, Le Plessis Robinson, Paris, France
    Search for more papers by this author
  • Catherine Blanc,

    1. UPMC Univ Paris 06, Paris, France
    2. INSERM, Plateforme de cytométrie, GH Pitié-Salpêtrière, Paris, France
    Search for more papers by this author
  • David Montani,

    1. Université Paris-Sud, Faculté de Médecine, Kremlin-Bicêtre, Paris, France
    2. AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, DHU TORINO «Thorax Innovation», Hôpital de Bicêtre, Le Kremlin-Bicêtre, Paris, France
    3. INSERM UMR_S 999, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, LabEx LERMIT, Le Plessis Robinson, Paris, France
    Search for more papers by this author
  • Mélanie Eyries,

    1. INSERM UMR_S 956, Paris, France
    2. ICAN Institute for Cardiometabolism and Nutrition, Paris, France
    3. AP-HP, Département de génétique, GH Pitié-Salpêtrière, Paris, France
    Search for more papers by this author
  • Françoise Imbert-Bismut,

    1. AP-HP, Laboratoire de Biochimie métabolique, GH Pitié-Salpêtrière, Paris, France
    Search for more papers by this author
  • Antoine Pacheco,

    1. Beckman Coulter France S.A.S., Villepinte, France
    Search for more papers by this author
  • Jacques Vigne,

    1. Beckman Coulter France S.A.S., Villepinte, France
    Search for more papers by this author
  • David-Alexandre Tregouet,

    1. UPMC Univ Paris 06, Paris, France
    2. ICAN Institute for Cardiometabolism and Nutrition, Paris, France
    3. INSERM UMR_S 937, Paris, France
    Search for more papers by this author
  • Marc Humbert,

    1. Université Paris-Sud, Faculté de Médecine, Kremlin-Bicêtre, Paris, France
    2. AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation Respiratoire, DHU TORINO «Thorax Innovation», Hôpital de Bicêtre, Le Kremlin-Bicêtre, Paris, France
    3. INSERM UMR_S 999, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, LabEx LERMIT, Le Plessis Robinson, Paris, France
    Search for more papers by this author
  • Florent Soubrier

    1. INSERM UMR_S 956, Paris, France
    2. UPMC Univ Paris 06, Paris, France
    3. ICAN Institute for Cardiometabolism and Nutrition, Paris, France
    4. AP-HP, Département de génétique, GH Pitié-Salpêtrière, Paris, France
    Search for more papers by this author

Florent Soubrier, INSERM U956, Faculté de médecine Pitié-Salpétrière, 75013 Paris, France. Tel.: 33 1 40 77 97 43; fax: 33 1 40 77 96 45; e-mail: florent.soubrier@upmc.fr

Abstract

Eur J Clin Invest 2012

Abstract

Background  The various aetiologies and risk factors for pulmonary arterial hypertension (PAH) lead to close phenotypes with small differences. Plasma microparticles have been shown to be increased in vascular pathologies including PAH. The aim of this study was to determine whether the levels of endothelial and platelet-derived microparticles could vary between different forms of PAH: idiopathic PAH (iPAH), heritable PAH associated with BMPR2 (Bone morphogenetic protein receptor, type II) mutation (hPAH) and PAH associated with connective tissue diseases (aPAH).

Materials and methods  Microparticles were analysed using flow cytometry in plasma from controls and iPAH, hPAH and aPAH patients. Platelet-derived MP (PMP) were defined as CD31+/CD41+ and endothelial-derived MP (EMP) as CD31+/CD41. Two populations of PMP were isolated according to their size, defining small PMP (0·3–0·5 μm) and large PMP (0·5–0·9 μm). BMPR2 genotype, clinical and biologic parameters were recorded.

Results  EMP and small PMP levels in iPAH, hPAH and aPAH were similar and were significantly increased as compared with controls. No differences in large PMP levels were observed. After adjusting for age, sex, proBNP and CRP, EMP and small PMP levels did not correlate with clinical parameters.

Conclusions  iPAH, hPAH and aPAH were characterized by increased levels of EMP and of small PMP, a new class of PMP which seems to be differentially produced than large PMP.

Ancillary